Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-07 |
2024-09 |
-5.22 |
N/A |
N/A |
N/A |
2024-08-13 |
2024-06 |
-3.94 |
-2.05 |
1.89 |
47.97% |
2024-05-15 |
2024-03 |
-1.5 |
-2.28 |
-0.78 |
-52.00% |
2024-04-22 |
2023-12 |
0 |
-0.8 |
N/A |
N/A |
2023-11-02 |
2023-09 |
-2.8 |
-1.8 |
1 |
35.71% |
2023-08-03 |
2023-06 |
-1.6 |
-2.8 |
-1.2 |
-75.00% |
Date |
Firm |
Action |
From |
To |
2023-09-21 |
Needham |
Upgrade |
Buy |
Buy |
2023-09-21 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-07 |
Needham |
Upgrade |
Buy |
Buy |
2023-09-06 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-06 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-08-03 |
Needham |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-03-31 |
ABDOLLAHIAN NEIL |
Officer |
57.47K |
Sale |
2022-09-11 |
DARUWALA PAUL |
Chief Operating Officer |
221.10K |
Sale |
2021-09-12 |
FRANSON TIMOTHY R |
Director |
11.00K |
Purchase |
2022-03-30 |
JOHNSON BRADY |
Officer |
59.37K |
Stock Award(Grant) |
2024-07-18 |
RA CAPITAL MANAGEMENT, L.P. |
Unknown |
0.00 |
Conversion of Exercise of derivative security |
2024-09-10 |
SANDISON TAYLOR |
Officer |
23.07K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
BVF Inc. |
6.86M |
7.75M |
7.60% |
2023-06-29 |
Nantahala Capital Management, LLC |
3.96M |
4.48M |
4.39% |
2023-06-29 |
Vanguard Group Inc |
3.21M |
3.62M |
3.55% |
2023-06-29 |
Alethea Capital Management, LLC |
1.63M |
1.84M |
1.80% |
2023-06-29 |
Renaissance Technologies, LLC |
1.55M |
1.75M |
1.72% |
2023-06-29 |
Point72 Asset Management, L.P. |
1.25M |
1.41M |
1.39% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.17M |
2.45M |
2.40% |
2023-06-29 |
Vanguard Extended Market Index Fund |
908.10K |
1.03M |
1.01% |
2023-05-30 |
Fidelity Extended Market Index Fund |
344.07K |
457.62K |
0.38% |
2023-08-30 |
iShares Micro Cap ETF |
189.96K |
148.95K |
0.21% |
2023-05-30 |
Fidelity Total Market Index Fund |
123.53K |
164.29K |
0.14% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
85.34K |
113.50K |
0.09% |
Split |
Date |
1 : 20 |
2024-04-24 |